My Cart

GIPR

GIPR Background

This gene encodes a G-protein coupled receptor for gastric inhibitory polypeptide (GIP), which was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release in the presence of elevated glucose. Mice lacking this gene exhibit higher blood glucose levels with impaired initial insulin response after oral glucose load. Defect in this gene thus may contribute to the pathogenesis of diabetes. [provided by RefSeq, Oct 2011]

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AT-02AT-02Phase 2 ClinicalAttralus IncImmunoglobulin Light-chain Amyloidosis; Amyloidosis
Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)Phase 1 ClinicalUniversity Of California San DiegoLeukemia, Myeloid, Acute
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
ImlifidaseMac-1ApprovedHansamed IncIdefirixEURejection of renal transplantationHansa Biopharma Ab2020-08-25Rejection of renal transplantation; Kidney Diseases; Purpura, Thrombotic Thrombocytopenic; Rejection of organ transplantation; Renal Insufficiency, Chronic; Guillain-Barre Syndrome; Kidney Failure, Chronic
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information